http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110051846-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d94573ab2c57e8b193f3a22accddf9fe |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2019-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb592536d0e14d6994bf1c34a7de43c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f930fccc1a4c9f667eaa7008b67ac6b |
| publicationDate | 2019-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110051846-A |
| titleOfInvention | A kind of antineoplastic pharmaceutical compositions and its application based on humoral immunity blocking |
| abstract | The present invention provides a kind of antineoplastic pharmaceutical compositions blocked based on humoral immunity and its applications, and illustrate its biological mechanism in tumor therapeutic procedure.The antineoplastic pharmaceutical compositions blocked based on humoral immunity include epigenetic inhibitor and humoral immunity blocker.The composition can effectively restore the anti-tumor immune response of T cell, preferably inhibit tumour growth.Simultaneously as humoral immunity blocker removes negative feedback brought by epigenetic inhibitor, the two drug combination produces synergistic effect.Therefore, which has preferable potential applicability in clinical practice. |
| priorityDate | 2019-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.